• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性肠病研究面临的挑战:实用临床研究。

Challenges in IBD Research: Pragmatic Clinical Research.

机构信息

Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Aurora, CO, USA.

University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.

出版信息

Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S40-S47. doi: 10.1093/ibd/izz085.

DOI:10.1093/ibd/izz085
PMID:31095704
Abstract

Pragmatic clinical research is part of five focus areas of the Challenges in IBD research document, which also includes preclinical human IBD mechanisms, environmental triggers, novel technologies, and precision medicine. The Challenges in IBD research document provides a comprehensive overview of current gaps in inflammatory bowel diseases (IBD) research and delivers actionable approaches to address them. It is the result of multidisciplinary input from scientists, clinicians, patients, and funders, and represents a valuable resource for patient centric research prioritization. In particular, the pragmatic clinical research section is focused on highlighting gaps that need to be addressed in order to optimize and standardize IBD care. Identified gaps include: 1) understanding the incidence and prevalence of IBD; 2) evaluating medication positioning to increase therapeutic effectiveness; 3) understanding the utility of therapeutic drug monitoring (TDM); 4) studying pain management; and 5) understanding healthcare economics and resources utilization. To address these gaps, there is a need to emphasize the use of emerging data sources and real-world evidence to better understand epidemiologic and therapeutic trends in IBD, expanding on existing data to better understand how and where we should improve care. Proposed approaches include epidemiological studies in ethnically and geographically diverse cohorts to estimate incidence and prevalence of IBD and impact of diversity on treatment patterns and outcomes. The implementation of new clinical trial design and methodologies will be essential to evaluate optimal medication positioning, appropriate use of TDM in adults and children, and multidisciplinary approaches to IBD pain management and its impact on healthcare resources.

摘要

实用临床研究是《炎症性肠病研究挑战》文件五个重点领域之一,该文件还包括临床前人类 IBD 机制、环境触发因素、新技术和精准医学。《炎症性肠病研究挑战》文件全面概述了炎症性肠病 (IBD) 研究当前的差距,并提供了应对这些差距的可行方法。它是来自科学家、临床医生、患者和资助者的多学科投入的结果,是患者为中心的研究优先级别的宝贵资源。特别是,实用临床研究部分侧重于突出需要解决的差距,以优化和标准化 IBD 护理。确定的差距包括:1)了解 IBD 的发病率和患病率;2)评估药物定位以提高治疗效果;3)了解治疗药物监测 (TDM) 的实用性;4)研究疼痛管理;5)了解医疗保健经济学和资源利用。为了解决这些差距,需要强调利用新兴数据源和真实世界证据,以更好地了解 IBD 的流行病学和治疗趋势,扩大现有数据以更好地了解我们应该如何改进护理。拟议的方法包括在种族和地理多样化的队列中进行流行病学研究,以估计 IBD 的发病率和患病率,以及多样性对治疗模式和结果的影响。实施新的临床试验设计和方法对于评估最佳药物定位、TDM 在成人和儿童中的适当使用以及多学科方法治疗 IBD 疼痛及其对医疗保健资源的影响至关重要。

相似文献

1
Challenges in IBD Research: Pragmatic Clinical Research.炎症性肠病研究面临的挑战:实用临床研究。
Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S40-S47. doi: 10.1093/ibd/izz085.
2
Challenges in IBD Research: Precision Medicine.炎症性肠病研究的挑战:精准医学。
Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S31-S39. doi: 10.1093/ibd/izz078.
3
Challenges in IBD Research: Preclinical Human IBD Mechanisms.炎症性肠病研究面临的挑战:临床前人类 IBD 机制。
Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S5-S12. doi: 10.1093/ibd/izz075.
4
Challenges in IBD Research: Environmental Triggers.炎症性肠病研究的挑战:环境触发因素。
Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S13-S23. doi: 10.1093/ibd/izz076.
5
Challenges in IBD Research: Novel Technologies.炎症性肠病研究的挑战:新技术。
Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S24-S30. doi: 10.1093/ibd/izz077.
6
Challenges in IBD Research 2024: Precision Medicine.2024 年炎症性肠病研究面临的挑战:精准医学。
Inflamm Bowel Dis. 2024 May 23;30(Suppl 2):S39-S54. doi: 10.1093/ibd/izae084.
7
Challenges in IBD Research 2024: Pragmatic Clinical Research.2024 年炎症性肠病研究面临的挑战:实用临床研究。
Inflamm Bowel Dis. 2024 May 23;30(Suppl 2):S55-S66. doi: 10.1093/ibd/izae083.
8
Challenges in IBD Research 2024: Novel Technologies.2024 年炎症性肠病研究面临的挑战:新技术。
Inflamm Bowel Dis. 2024 May 23;30(Suppl 2):S30-S38. doi: 10.1093/ibd/izae082.
9
Challenges in IBD Research 2024: Preclinical Human IBD Mechanisms.2024 年炎症性肠病研究面临的挑战:临床前人类 IBD 机制。
Inflamm Bowel Dis. 2024 May 23;30(Suppl 2):S5-S18. doi: 10.1093/ibd/izae081.
10
Overview to Challenges in IBD 2024-2029.IBD 2024-2029 年挑战概述。
Inflamm Bowel Dis. 2024 May 23;30(Suppl 2):S1-S4. doi: 10.1093/ibd/izae092.

引用本文的文献

1
Gut Feeling: Biomarkers and Biosensors' Potential in Revolutionizing Inflammatory Bowel Disease (IBD) Diagnosis and Prognosis-A Comprehensive Review.直觉:生物标志物和生物传感器在革新炎症性肠病(IBD)诊断和预后方面的潜力——全面综述
Biosensors (Basel). 2025 Aug 7;15(8):513. doi: 10.3390/bios15080513.
2
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial.炎症性肠病患者在接受先进疗法后症状缓解情况下的内镜缓解达标治疗(QUOTIENT):一项开放标签、多中心、实用性随机对照试验的原理、设计与方案
BMJ Open Gastroenterol. 2025 Mar 31;12(1):e001615. doi: 10.1136/bmjgast-2024-001615.
3
Challenges in IBD Research 2024: Preclinical Human IBD Mechanisms.2024 年炎症性肠病研究面临的挑战:临床前人类 IBD 机制。
Inflamm Bowel Dis. 2024 May 23;30(Suppl 2):S5-S18. doi: 10.1093/ibd/izae081.
4
Prevalence and Appropriateness of Polypharmacy in Older Adults with Inflammatory Bowel Diseases.炎症性肠病老年患者多重用药的患病率及合理性
Dig Dis Sci. 2024 Mar;69(3):766-774. doi: 10.1007/s10620-023-08250-3. Epub 2024 Jan 25.
5
The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-Children and Adolescents with IBD.2023年炎症性肠病在加拿大的影响:特殊人群——炎症性肠病患儿和青少年
J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S35-S44. doi: 10.1093/jcag/gwad016. eCollection 2023 Sep.
6
Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial Data.5-氨基水杨酸联合治疗对炎症性肠病患者维得利珠单抗疗效和安全性的影响:临床试验数据的事后分析。
J Crohns Colitis. 2023 Dec 30;17(12):1949-1961. doi: 10.1093/ecco-jcc/jjad113.
7
Inflammatory Bowel Disease Prevalence: Surveillance data from the U.S. National Health and Nutrition Examination Survey.炎症性肠病患病率:来自美国国家健康与营养检查调查的监测数据。
Prev Med Rep. 2023 Mar 9;33:102173. doi: 10.1016/j.pmedr.2023.102173. eCollection 2023 Jun.
8
A Missing Piece of the Puzzle: Patient and Provider Perspectives on Pain Management Needs and Opioid Prescribing in Inflammatory Bowel Disease Care.难题中的缺失环节:患者与医疗服务提供者对炎症性肠病护理中疼痛管理需求及阿片类药物处方的看法
Crohns Colitis 360. 2022 Sep 8;4(3):otac033. doi: 10.1093/crocol/otac033. eCollection 2022 Jul.
9
Chronic Abdominal Pain in IBD Research Initiative: Unraveling Biological Mechanisms and Patient Heterogeneity to Personalize Treatment and Improve Clinical Outcomes.炎症性肠病慢性腹痛研究倡议:揭示生物学机制和患者异质性以实现个性化治疗并改善临床结局
Crohns Colitis 360. 2021 Jun 9;3(3):otab034. doi: 10.1093/crocol/otab034. eCollection 2021 Jul.
10
Hance Inhibits Ulcerative Colitis and Colitis-Associated Secondary Liver Damage of Mice by Enhancing Antioxidation Activity.Hance 通过增强抗氧化活性抑制溃疡性结肠炎和结肠炎相关的小鼠继发性肝损伤。
Oxid Med Cell Longev. 2021 Dec 18;2021:2617881. doi: 10.1155/2021/2617881. eCollection 2021.